HR070803

Phase 3Small molecule

JJiangsu HengRui Medicine Co., Ltd.

HR070803 is one of 87 small molecule programs targeting Colorectal Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Colorectal CancerActive, not recruiting

Pancreatic CancerNot yet recruiting

Colorectal CancerPhase 3

Active, not recruiting

Pancreatic CancerPhase 2

Not yet recruiting

Competition

Competitive Landscape

307 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

HR070803

JJiangsu HengRui Medicine Co., Ltd.

Phase 3

1 2

Medrol

Pfizer

Preclinical

1 3

Byetta

AstraZeneca

Preclinical

1 4

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 5

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 6

Ayvakit Sprinkle

MMemorial Sloan Kettering Cancer Center

Preclinical

1 7

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 8

Active Comparator

Moderna

Preclinical

1 9

Secretin-Ferring

Ferring

Preclinical

1 10

Sulfonylureas

Eli Lilly

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2/3Active, not recruiting

Colorectal Cancer

NCT05945901

Q4 2027

Phase 2Not yet recruiting

Pancreatic Cancer

NCT06383078

Clinical

Trials by Indication[1]

Colorectal Cancer1 trial

A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer

Active, not recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 2/3·NCT05945901·669 enrolled

Esophageal Cancer1 trial

A Phase II Study of HR070803 in the Treatment of Advanced Esophageal Cancer

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT05425472·30 enrolled

Pancreatic Cancer1 trial

HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer

Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06383078·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for HR070803. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HR070803 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HR070803. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jiangsu HengRui Medicine Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: JJiangsu HengRui Medicine Co., Ltd.

HR070803

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Trials by Indication[1]

Colorectal Cancer1 trial

Esophageal Cancer1 trial

Pancreatic Cancer1 trial

References

Drug Info

Quick Facts

Related News